| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Erasmus University, Department of Cell Biology and Genetics, P. O. Box 1738, 3000 DR Rotterdam, the Netherlands [H. B. B., J. W., A. d. K., A. H.]; Unite INSERM U 301, Institut de Genetique Moleculaire, 27 Rue Juliette Dodu, 75010 Paris, France [M. L. C., O. B., R. B.]; Imperial Cancer Research Fund, Department of Medical Oncology, St. Bartholomew's Hospital Medical College, London EC1M 6BQ, United Kingdom [D. M. L., B. D. Y.]; Dutch Childhood Leukemia Study Group, Leyweg 299, 2545 CJ The Hague, the Netherlands [E. v. W.]; and University of California, University of California Davis Medical Center, Hematology and Oncology, Sacramento, California 95816 [J. W.]
Ten AML-M4/M5 patients' samples containing a t(10;11) translocation, but with different cytogenetic breakpoints on chromosome 11q (11q1323), were studied by G- and R-banding and fluorescent in situ hybridization. Southern blotting analysis, studied in five patients, revealed a rearranged MLL gene. Reverse transcription-PCR analysis carried out in six patients showed a 5' MLL-3' AF-10 fusion transcript. Fluorescent in situ hybridization studies suggested that in 8 of 10 patients, the rearrangement/fusion transcript resulted from an inversion of a part of 11q (q13q23) translocated to 10p12. In the other two patients, it is assumed that an inversion/translocation has occurred of a part of 10p to the der(11).
The results suggest that the orientation of the AF-10 gene on 10p is 5' telomeric and 3' centromeric. This is the first example of opposite-oriented genes being involved in translocation to yield fusion transcripts.
1 This study was supported by European Union Grant CT93-0055 (B. B.), European Union Grant CA CT94-1703 (A. H., B. D. Y., R. B.), by the Fondation contre la Leucemie, and by the Caroline Lawson Trust for Children's Cancer Research.
2 To whom requests for reprints should be addressed.
Received 7/11/95. Accepted 8/18/95.
This article has been cited by other articles:
![]() |
A. Reiter, J. Sohal, S. Kulkarni, A. Chase, D. H.C. Macdonald, R. C.T. Aguiar, C. Goncalves, J. M. Hernandez, B. A. Jennings, J. M. Goldman, et al. Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome Blood, September 1, 1998; 92(5): 1735 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Taki, N. Shibuya, M. Taniwaki, R. Hanada, K. Morishita, F. Bessho, M. Yanagisawa, and Y. Hayashi ABI-1, a Human Homolog to Mouse Abl-Interactor 1, Fuses the MLL Gene in Acute Myeloid Leukemia With t(10;11)(p11.2;q23) Blood, August 15, 1998; 92(4): 1125 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.H. Dreyling, K. Schrader, C. Fonatsch, B. Schlegelberger, D. Haase, C. Schoch, W.-D. Ludwig, H. Loffler, T. Buchner, B. Wormann, et al. MLL and CALM Are Fused to AF10 in Morphologically Distinct Subsets of Acute Leukemia With Translocation t(10;11): Both Rearrangements Are Associated With a Poor Prognosis Blood, June 15, 1998; 91(12): 4662 - 4667. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |